Category: PRESS RELEASES

The Company will present its updated 2024 Strategic Business Plan, hosting an in-person and virtual event with presentations starting at 12 noon EST / 6:00 p.m. CET.
Follow the full event live at: capitalmarketsday.cnhindustrial.com

London, February 22, 2022

CNH Industrial (NYSE: CNHI / MI: CNHI) will host its Capital Markets Day today at The Fillmore Theater in Miami Beach, Florida, USA.

Presentations will commence at 12 noon EST / 6:00 p.m. CET and proceed as follows:

All event presentations will be made available in due course through the CNH Industrial corporate website.

CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company that sustainably advances the noble work of agriculture and construction workers. The Company provides the strategic direction, R&D capabilities, and investments that enable the success of its five core Brands: Case IH, New Holland Agriculture and STEYR, supplying 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment delivering a full lineup of construction products that make the industry more productive. Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 35,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.

For more information and the latest financial and sustainability reports visit: cnhindustrial.com

For news from CNH Industrial and its Brands visit: media.cnhindustrial.com

Contacts:

Media Relations
Email: mediarelations@cnhind.com

Investor Relations
Email: investor.relations@cnhind.com

Attachments

• 20220222_PR_CNH_Industrial_CMD_Follow_Live
• 20220222_CS_CNH_Industrial_CMD_Segui_ in_diretta
• CNH Industrial Capital Markets Day

Jeito Capital co-leads $65 million Series A financing in EyeBio

• EyeBio is a newly launched global company developing the next generation of eye disease therapies
• Founded by two pioneers in ophthalmology drug development to build and advance diversified pipeline of ocular therapies
• Jeito selects EyeBio as its 8^th investment and continues to build a strong & diversified portfolio of companies with groundbreaking therapies in areas of high unmet need

Paris, France, 22 February 2022 – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led a $65 million Series A financing round in EyeBiotech Limited (“EyeBio”), a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases. The Series A brings together a team of international executives and investors with an extensive track record for developing ground-breaking ophthalmology therapies.

Jeito co-led the financing with SV Health Investors and Samsara BioCapital, with additional financial backing from MRL Ventures. Jeito Capital’s newly appointed Partner, Andreas Wallnoefer, will join EyeBio’s Board of Directors, Kate Bingham, Managing Partner at SV Health Investors, and Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital.

EyeBio was founded in August 2021 by David Guyer, M.D., and Anthony P. Adamis, M.D., working with collaborators at SV Health Investors, who provided seed funding and helped to recruit leadership and to initiate pipeline development. Previously, Dr. Guyer and Dr. Adamis co-founded Eyetech Pharmaceuticals, where they developed and commercialized the first anti-vascular endothelial growth factor (anti-VEGF) drug for the treatment of age-related macular degeneration (AMD) in 2005.

EyeBio launches with a specific mission: to protect, restore, and improve vision for people who are underserved by available eye disease therapies. The company will use proceeds from the Series A to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches. The company has established a footprint in Europe to take advantage of the innovation-friendly environment for clinical trial development.

Prior to co-founding EyeBio, Dr. Guyer served as executive chairman and CEO of Iveric Bio, a biopharmaceutical company developing novel treatments for retinal diseases. Dr. Adamis previously served as Senior Vice President of Development Innovation at Genentech, a member of The Roche Group, where he led development programs in multiple therapeutic areas and oversaw the U.S. Food and Drug Administration (FDA) approval of 25 drugs including in ophthalmology, e.g Vabysmo® (faricimab-svoa).

Rafaèle Tordjman, Founder and CEO at Jeito, said: “We are pleased to have co-led this financing in EyeBio alongside high-quality international investors. At Jeito, we are continuing to identify and invest in companies that have the potential to be market leaders in the development of new and improved therapies for patients in areas of unmet need. EyeBio is led by two pioneers in the field of ophthalmology together with an ambitious team of highly experienced experts with a proven track record in developing ground-breaking therapies. We look forward to supporting the growth of the company in the long term as it builds its disruptive pipeline and accelerates the development and approval of next generation therapies for patients.”

Prior to joining Jeito, Andreas Wallnoefer was General Partner at BioMed fund, and a senior executive at Roche and involved in several successful product development programs. He was instrumental in the development and securing FDA approval for Vabysmo® (faricimab-svoa) for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Andreas Wallnoefer, Partner at Jeito, said: “EyeBio is a new and exciting company that has the potential to disrupt the ophthalmology space, where there are a tremendous number of patients faced with a lack of durable and effective treatments. I look forward to working closely with the team and lending my expertise in product development to help guide the company in its ultimate goal of protecting, restoring, and improving vision for people who are underserved by currently available eye disease therapies.”

“Advances in research are revealing new opportunities to translate science into solutions that serve patients with eye diseases who have urgent and unaddressed medical needs,” said Dr. Guyer, Co-Founder, President, and Chief Executive Officer of EyeBio. “Patients and physicians deserve new and better therapies, which is why this team of serial disruptors has banded together to form EyeBio. We are launching at an exciting time, and we are equipped with the resources to make a significant impact.”

About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito_life or LinkedIn.

About EyeBio
Eyebiotech Limited (EyeBio) is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. Founded in August 2021 by David Guyer, M.D. and Anthony P. Adamis, M.D., EyeBio has a leadership team composed of serial disruptors in ophthalmology drug development. With operations in the United States and the United Kingdom, EyeBio is building and advancing a pipeline of ocular therapies that combine scientifically robust targets with innovative translational approaches. For more information, please see www.eyebiotech.com.

For more information please contact:

Jeito Capital
Rafaèle Tordjman
Assia Mouhout, PA
assia@jeito.life
Tel : +33 6 76 49 37 94

Consilium Strategic Communications
Mary-Jane Elliott / Melissa Gardiner / Davide Salvi / Kris Lam
Jeito@consilium-comms.com
Tel: +44 (0) 20 3709 5700
TBWA Corporate
Marion Bougeard
Marion.bougeard@tbwa-corporate.com
Tel : +33 6 76 73 57 31

February 22, 2022

• 1.7 billion lives improved by Philips’ health technology products, services and solutions
• Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
• Continued carbon-neutrality in its own operations and supporting supply chain partners to decarbonize
• Publication of Philips Human Rights Report 2021 and Country Activity and Tax Report 2021 detailing its tax contributions for all countries it operates in

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an update on its key Environmental, Social, and Governance (ESG) achievements in 2021 as it continues to deliver innovative health technology solutions around the world. These 2021 ESG achievements include 1.7 billion lives improved by Philips’ healthcare and personal health products, services and solutions, 16% of sales derived from circular revenues, and continued carbon neutrality in its own operations.

“Inspired by our purpose to improve people’s health and well-being, we innovate solutions that deliver meaningful impact, while doing business responsibly and sustainably,” said Frans van Houten, CEO of Royal Philips. “I am proud that we again delivered on our ESG commitments, such as reaching 1.7 billion people with our products, services and solutions in 2021, including 167 million in underserved communities. Driven by the creativity and hard work of our global workforce, we will continue to raise the bar for ourselves and our partners across our entire value chain.”

Philips’ Environmental, Social, and Governance update is an integral part of the Philips Annual Report 2021, which was published earlier today. Highlights include:

Environmental:

• Circular revenues accounted for 16% of sales in 2021, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime, reusing refurbished parts and systems, as well as product rental models and operational leases. As part of Philips’ ambition to close the loop for all professional equipment by 2025, over 3,000 systems were returned to the company for responsible recycling/repurposing. In addition, Philips further reduced the amount of waste produced in its sites, realizing a 29% waste reduction compared to 2020. Of the waste that was produced, 87% was repurposed.
• While already carbon neutral in its own operations, Philips further reduced its remaining site-related CO₂ emissions by 12% in 2021 by installing solar panels and making its buildings more energy efficient. The company also continued to shift to low carbon transport modes, reducing its aviation-related emissions by instigating a stricter air freight policy, optimizing its warehouse locations, and electrifying its leased vehicle fleet.
• Philips stepped up its supplier sustainability program with the aim of at least 50% of its suppliers (based on spend) committing to science-based targets (SBTs) for CO₂ emissions reduction by 2025. This major push to decarbonize its supply chain will have a potential impact seven times greater than the reduction of CO₂ emissions from Philips’ own operations. In 2021, 28% of Philips’ purchases were made at suppliers that have committed to science-based CO₂ reduction targets. Philips’ supplier engagement actions on climate change were recognized by CDP, the not-for-profit environmental impact disclosure organization, for the fifth year in a row in 2021.

Social:

• Philips reached 1.7 billion people with its products and services in 2021, of which 167 million in underserved communities (which the Philips Foundation contributed to), taking the company closer to its goal of improving 2 billion lives per year by 2025 with 300 million in underserved communities.
• As part of its ESG commitments, Philips aims to improve the lives of 1 million workers in its supply chain by 2025. The number of employees positively impacted at suppliers participating in Philips’ Supplier Sustainability Program increased to approximately 430,000 in 2021.
• Philips’ average employee engagement score remained high at 79%, exceeding the Fortune 500 benchmark. Philips was awarded a top spot on the Forbes ‘America’s Best Employers of 2021’ list, ranking 135 among the top 500 large companies in America based on an independent survey of employees.
• Philips raised its commitment of gender diversity in senior leadership positions to 35% by the end of 2025, from its original commitment of 30%. In 2021, the percentage of females in senior leadership positions increased to 28%.

Governance:

• All of Philips’ ESG data is externally audited at the highest level, building on Philips’ strong track record of transparency in its ESG plans, actions, and reporting. Philips won the annual Dutch Kristal Prize 2021 for its transparency in reporting, specifically regarding climate related matters.
• For the second year, Philips published its Country Activity and Tax Report 2021 detailing its tax contributions for all countries it operates in.
• To mark 2021 United Nations Human Rights Day, Philips published the Philips Human Rights Report 2021 – an update on Philips’ progress in addressing key human rights over the past year, along with the company’s plans for continuous improvement.

More information about how Philips is partnering with stakeholders to drive environmental, social, and governance priorities and make a global impact is available here.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446
E-mail: ben.zwirs@philips.com

Joost Maltha
Philips Global Press Office
Tel: +31 6 10558116
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips Lumify being used on a pregnant woman
• Reuse and refurbishment of returned equipment
• Solar panels

February 22, 2022

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2021.

Philips’ Annual Report 2021 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 10, 2022. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course.

Philips filed the Annual Report 2021 with Netherlands Authority for the Financial Markets in European Single Electronic Format (ESEF) and expects to file the report on Form 20-F with the U.S. Securities and Exchange Commission later today (www.sec.gov).

The Annual Report 2021 (in ESEF and on Form 20-F) will be available to shareholders and other interested parties at www.results.philips.com. A printed copy can be obtained free of charge upon written request to the following email address: annual.report@philips.com.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Attachment

• Patient wearing Philips Biosensor BX-100

SINGAPORE, Feb. 22, 2022 (GLOBE NEWSWIRE) — Navis Capital Partners and SK ecoplant, South Korea’s leading environmental service provider, have signed a definitive agreement for the acquisition of 100% of TES by SK ecoplant. The transaction values TES at an enterprise value of US$1 billion and is expected to close in Q2 of 2022.

SK ecoplant has long viewed the sustainable IT lifecycle market strategically as a means to help create a zero-waste, zero-pollution circular economy. The acquisition of TES will be a key driver in accelerating its entry into the global market for environmental services. The acquisition will also maximize synergies that both companies have in battery recycling and plastics innovations, as well as broadly accelerate the growth plan for TES’s existing business strategy.

“The acquisition of TES will be a milestone for SK ecoplant to become a leader in the exponentially growing global sustainable IT lifecycle services market,” Park Kyung-Il, CEO of SK ecoplant, said. He added, “The company will continue to invest in companies with high growth potential and innovative technology and pursue M&A activity to become a global-leading environmental solutions provider.”

“TES’s mission is to make a decade of difference by securely, safely, and sustainably transforming and repurposing one billion kilograms of assets by 2030,” said Gary Steele, TES’s Chief Executive Officer. “SK ecoplant’s experience and shared vision of a more sustainable world make them the perfect partner for TES. The commitment represented by SK’s investment reaffirms that, and we couldn’t be more excited about working with them to offer sustainable technology solutions that drive the circular economy.”

Jean-Christophe Marti, the Senior Partner at Navis, commented: “Working with the TES team to help transform the business over the last eight years has been a privilege. Under Navis’s stewardship, TES has grown to become an industry leader with an excellent management team, strong operational processes that have raised the bar for ESG compliance across the industry, and a global network of facilities to serve its blue-chip clients. TES is also ideally positioned to be a key player in the upcoming global energy transition. SK ecoplant, a leader in the Korean environmental services market, is ideally suited to help take TES to the next level.”

About TES

Since our formation in 2005, TES has grown to become a global leader in sustainable technology services and bespoke solutions that help clients manage the commissioning, deployment, and retirement of technology devices and components.

We provide comprehensive services for technology devices throughout their lifecycle — from deployment to decommissioning to disposition — all the way through to recycling and end-of-life repurposing. This includes innovating new processes to leverage the value locked in assets if they are to be recycled, such as our proprietary lithium battery recycling process, which extracts scarce materials from used batteries at purity rates high enough that they can be reused in the manufacturing supply chain.

We have made it our mission to make a decade of difference by securely, safely, and sustainably transforming and repurposing one billion kgs of assets by 2030. Our 43 owned facilities across 21 countries offer unmatched service-level consistency, consistent commercials, lower logistics costs, local compliance experts in-region, support in local time zones and languages, and a deep understanding of transboundary movement globally. For more information, contact Eric Ingebretsen at eric.ingebretse@tes-amm.com or visit www.tes-amm.com.

About SK ecoplant 

Launched in 1977 under the name SK E&C, SK ecoplant possesses the highest levels of technical skills and construction capacity in sectors such as chemical and power plants, infrastructure, construction, and housing. The company recently set its new goal to become a leading global eco-friendly and new energy company that connects the environment, people, and finance through technology, ultimately contributing to sustainable lives for all. For more information, visit www.skecoplant.com/en.

About Navis Capital Partners 

Founded in 1998, Navis manages approximately US$5 billion in private equity capital and focuses on investments primarily in and around Asia. Navis contributes both capital and management expertise to a limited number of well-positioned companies with the objective of directing strategic, operational, and financial improvements. Navis has a long and proven track record in pan-Asian private equity, with over 85 control transactions across the Asian region completed since its establishment. For more information, visit www.naviscapital.com.

This content was issued through the press release distribution service at Newswire.com.

Stewardship Approach Safeguards All Elements of Contract Breeding Services

RENSSELAER, N.Y., Feb. 21, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, launched Cage+, a holistic, innovative approach to murine contract breeding services. Cage+ delivers complete stewardship of projects from start to finish, allowing investigators to focus on research with confidence that animal model supply is reliable, at the highest quality, and on budget.

Biomedical and pharmaceutical research has profoundly changed over the past two decades. Studies are more advanced and rapid-paced, compressing the time to produce experimental data required to support well-informed decisions. The novel animal models generated to support these advanced studies have become more complex and precise. Yet, while the contract research service industry has kept pace with biomedical research advancements, the contract breeding industry has remained largely unchanged since the early 1990s. Most providers continue to place the project planning and management burden on investigators, who have neither the time nor expertise to direct service providers on how best to design and manage scaled production of complex animal models.

Taconic’s Cage+ Colony Management Solutions closes the gap between biomedical research program demands and the antiquated approach offered by many contract breeding services. Cage+ employs a holistic approach, combining standard animal breeding and husbandry elements with comprehensive breeding design expertise, project-specific methodology to reduce animal welfare concerns, budget monitoring, and proactive project management and communication. Additionally, this all-encompassing program rapidly expands breeding production through expert-led embryology methods, delivers internationally harmonized animal health standards, and includes the eTACONIC^® web-based project management tool, providing users access to colony information 24/7.

Cage+ allows investigators to fully leverage proven expertise in complex model design and breeding to advance research programs. When coupled with Taconic’s Custom Model Generation Solutions, Cage+ Colony Management Solutions brings a comprehensive and seamless “design to management” service, allowing clients to leverage the most complex genetically engineered models from initial design through to scaled production of study cohorts.

“Researchers should demand better from contract breeding service providers, and this view is the driving factor behind our Cage+ stewardship-based approach to colony management solutions,” said Dr. John Couse, vice president, scientific services. “With Cage+, researchers will view Taconic as an extension of their team, leveraging the collaboration of scientists and experts. Our approach allows investigators to focus their time, energy, and resources on research while trusting their custom model animal development and production to Taconic.”

To learn more about how Cage+ can improve your colony management experience and outcomes, please call 1-888-TACONIC (1-888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc. 
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates laboratories and breeding facilities in the US and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact: 
Aidan Bouchelle
Associate Director, Marketing Operations
1-518-949-7598
Aidan.Bouchelle@taconic.com